Novo Nordisk Gets EU Approval for Wegovy Oral Tablets, First GLP-1 for Weight Management

NVO2.91%
Novo Nordisk received European Union approval on July 15 for Wegovy oral tablets, becoming the first oral GLP-1 receptor agonist indicated for weight management. The company also obtained approval for a 7.2 mg single-dose pre-filled injection pen formulation.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments